University of Zürich

Neurimmune Holding Ag

Unversität Zürich

Tobias Welt

Jan Grimm

Roger Nitsch

Christoph Hock

Fabio Montrasio

Marcel Maier

Maria Grazia Barenco Montrasio

Jordan Mcafoose

Fabrice Heitz

Fabian Wirth

Jordan McAfoose

Provided are novel human copper-zinc superoxide dismutase, also known as superoxide dismutase 1 or SOD1, specific antibodies as well as fragments, derivatives and variants thereof as well as methods related thereto. Assays, kits, and solid supports related to antibodies specific for SOD1 are also disclosed. The antibody, immunoglobulin chain(s), as well as binding fragments, derivatives and variants thereof can be used in pharmaceutical and diagnostic compositions for SOD1 targeted immunotherapy and diagnosis, respectively.

Human anti-SOD1 antibodies

Described are molecules specifically binding to human islet amyloid polypeptide (hIAPP) also known as amylin, particularly human-derived antibodies as well as fragments, derivatives and variants thereof for antagonizing islet amyloid polypeptide (IAPP) induced &#x3b2;-cell damage and impaired glucose tolerance which are symptoms typically associated with diabetes mellitus type 2 (T2D).

Compounds capable of antagonizing islet amyloid polypeptide (IAPP) induced beta-cell damage and impaired glucose tolerance

Growing community of inventors

Zurich, Switzerland

Tobias Welt